GlassScriptPhysician profile
Manish Rungta
NPI 1205847944
$4,621.18
in general payments reported to CMS, 2019-2025
27 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $190 · 2021: $538 · 2022: $844 · 2023: $834 · 2024: $685 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.13 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.22 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $486.14 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $366.18 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $294.01 | 2019-2025 | |
| Pfizer INC. | $185.79 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $150.00 | 2025 | Livmarli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.53 | 2019-2023 | Trulance |
| Merck Sharp & Dohme LLC | $140.99 | 2019-2024 | Dificid |
| Genzyme Corporation | $80.55 | 2023-2024 | |
| Qol Medical, LLC | $69.81 | 2019-2023 | Sucraid |
| Janssen Biotech, INC. | $64.50 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $53.84 | 2019-2021 | |
| Conmed Corporation | $50.95 | 2024 | Conmed Generators |
| Daiichi Sankyo INC. | $45.46 | 2023-2024 | Injectafer |
| Redhill Biopharma INC. | $41.03 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.13 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $28.98 | 2025 | Rezdiffra |
| Allergan, INC. | $24.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.57 | 2022 | |
| Evoke Pharma, INC. | $23.19 | 2022 | |
| Organon LLC | $21.06 | 2022 | |
| Novo Nordisk INC | $19.75 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $17.78 | 2020 | |
| Ardelyx, INC. | $15.00 | 2022 | |
| Medtronic, INC. | $12.80 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Rungta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.